赛妥珠单抗治疗类风湿性关节炎疗效及不良反应的荟萃分析

发布时间：2018-03-04 23:14

本文选题：类风湿　切入点：关节炎　出处：《中国免疫学杂志》2017年02期 　论文类型：期刊论文

【摘要】：目的:探究赛妥珠单抗治疗类风湿性关节炎的有效性及安全性。方法:计算机检索Pubmed、Medline、Embase、The Cochrane Library、万方数据库(WANFANG)、相关期刊论文(CNKI)、中国生物医学文献数据库中关于赛妥珠单抗与安慰剂治疗类风湿性关节炎的随机对照研究(Randomized controlled trials,RCTs),检索时限均为建库至2015年3月。采用Rev Man5.3软件进行统计分析。结果:共纳入10篇文献、8项研究,纳入文献质量均较高,本meta分析结果显示CZP在改善类风湿患者病情的疗效(ACR20、ACR50、ACR70),关节疾病活动性评分,患者对疾病活动性评价指标(HAQ-DI、关节疼痛、疲劳)方面优于安慰剂组。在轻度、中度、重度不良反应方面两组差异无统计学意义,CZP并未增加不良反应的发生率。结论:CZP能减缓患者关节炎症进展,改善患者关节功能,提高患者生活质量,短期安全性较高,CZP长期疗效及安全性有待于进一步研究证实。
[Abstract]:Objective: to investigate the efficacy and safety of Seytozumab in the treatment of rheumatoid arthritis (RA). Methods: a computer-based search of Pubmedmedus MedlineEmbase (Cochrane Library), Wanfang database (WANFANGG), China Journal Full-Text Database (CNKINGA) and Chinese Biomedical Literature Database (CBM) was conducted. A randomized controlled study on the treatment of rheumatoid arthritis with tozhu McAb and placebo was conducted. The search time was built up to March 2015. Rev Man5.3 software was used to carry out statistical analysis. Results: a total of 10 articles and 8 studies were included in the study. The results of meta analysis showed that CZP was superior to the placebo group in improving the curative effect of rheumatoid disease (ACR20ACR50 / ACR70), evaluating the activity of joint disease and evaluating the index of disease activity (HAQ-DI, joint pain, fatigue) in patients with mild rheumatoid disease, the results of meta analysis showed that CZP was superior to the placebo group in the treatment of rheumatoid disease. There was no significant difference in moderate and severe adverse reactions between the two groups. CZP did not increase the incidence of adverse reactions. Conclusion: CZP can slow down the progression of arthritis, improve the joint function and improve the quality of life of the patients. The long-term efficacy and safety of CZP with high short-term safety need to be confirmed by further study.
【作者单位】：重庆市肿瘤研究所/医院/癌症中心;
【分类号】：R593.22

【相似文献】